Several large cardiovascular outcome trials with novel glucose-lowering agents, namely, SGLT2i (SGLT2 inhibitors) and GLP-1 RA, have demonstrated robust and significant reductions in major adverse cardiovascular events and additional cardiovascular outcomes, such as hospitalizations for heart failure [29,30,31]. Here, GLP1R is linked to heart failure.